JACC:影响轻中度主动脉反流患者的自然病程的因素研究

2019-11-15 不详 MedSci原创

B期主动脉反流(AR)的自然发展病程尚不清楚。本研究的目的旨在评估AR进展的决定因素、速率和后果。本研究纳入分析了1077名≤中度慢性AR的患者(平均年龄66 ± 15),有196名(18%)患者存在基线水平的轻度AR,465名(43%)患者存在轻-中度AR,416名(39%)患者存在中度AR,进展为中重度AR(C/D期)的10年发生率分别为12%, 30%和53%。经过平均4.1年时间的随访,有

B期主动脉反流(AR)的自然发展病程尚不清楚。本研究的目的旨在评估AR进展的决定因素、速率和后果。

本研究纳入分析了1077名≤中度慢性AR的患者(平均年龄66 ± 15),有196名(18%)患者存在基线水平的轻度AR,465名(43%)患者存在轻-中度AR,416名(39%)患者存在中度AR,进展为中重度AR(C/D期)的10年发生率分别为12%, 30%和53%。经过平均4.1年时间的随访,有228名(21%)患者发生了病情进展,基线的AR严重程度和主动脉瓣的尺寸大小与病情的进展呈相关性(p ≤ 0.007),高血压和收缩压与疾病的进展不相关。有病情进展的患者心室的重塑速度、心功能下降速度更快。在随访中期,有242名患者死亡,差的预后与年龄、并发症、心功能、静息心率和左室射血分数呈相关性(p ≤ 0.003)。

研究结果显示,对于主动脉反流患者,有21%的B期患者会进展至C/D期,轻度、轻-中度和中度AR患者每5/3/1年重复一次心超检测是合理的。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2020-03-23 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-17 feifers
  6. [GetPortalCommentsPageByObjectIdResponse(id=1740368, encodeId=3a281e403681d, content=<a href='/topic/show?id=6f088626603' target=_blank style='color:#2F92EE;'>#自然病程#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86266, encryptionId=6f088626603, topicName=自然病程)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e00d34741921, createdName=siiner, createdTime=Fri Mar 20 03:43:00 CST 2020, time=2020-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854569, encodeId=8e1a185456905, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 23 09:43:00 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326395, encodeId=7fe51326395d5, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1415567, encodeId=b309141556ec1, content=<a href='/topic/show?id=04812314540' target=_blank style='color:#2F92EE;'>#主动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23145, encryptionId=04812314540, topicName=主动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77603112682, createdName=circumcision, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571668, encodeId=8ac515e166899, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Sun Nov 17 07:43:00 CST 2019, time=2019-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375203, encodeId=13fa3e5203e7, content=非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 17:43:31 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 14794e5bm67(暂无昵称)

    非常精彩,受益非浅

    0

相关资讯

Nat Med:液体活检新突破-精准预估肾脏病、心血管疾病风险!

近日,由格拉斯哥大学的研究小组领导的一项新的研究发现:使用基于胱抑素C测试的液体检查能够提前预估肾脏及心血管疾病风险,提供了更加精确的诊断,并为患者更好的预后奠定了基础。相关文章以“Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, morta

JACC:造影前做心脏磁共振是诊断心梗的新策略

非ST段抬高型心梗伴高敏肌钙蛋白水平升高的患者常规会接受有创的冠脉造影(ICA)检查,但经常会没有冠脉梗阻。本研究的目的旨在评估心脏磁共振(CMR)和计算机断层血管造影(CTA)是否可能成为ICA前的筛选手段。本次随机对照临床试验纳入分析了207名急性胸痛、高敏肌钙蛋白T升高(>14 ng/l)且超声心动图没有确诊的患者(平均年龄64岁,男性占62%)。当初始的CMR或CTA提示为心肌缺血、

Heart:急性冠脉综合征恢复期肌钙蛋白水平仍可预测患者死亡风险

高敏肌钙蛋白检测常用于急性冠脉综合征的诊断,但其在冠心病恢复期的作用尚不清楚。本研究的目的旨在研究急性冠状动脉综合征后一系列恢复期高敏心肌肌钙蛋白浓度的长期预后意义。在本次包含2140名急性冠脉综合征的前瞻性多中心观察研究中,我们对1776名患者进行了心脏肌钙蛋白I水平的检测,主要终点事件是心血管死亡事件。发病后4个月的肌钙蛋白浓度在99%的患者中是可检测的(年龄67±12岁,男性占72%),有4

JACC:重复心脏磁共振对急性心梗患者预后价值研究

心脏磁共振(CMR)被广泛应用在急性心梗(AM)的诊断上,CMR常会在6个月后复查一次以评估心梗的进展情况。然而,6个月CMR的临床和预后作用尚不清楚。 本研究纳入分析了ITAMY数据库中的187名急性心梗患者,并在患者发病后1周内(CMR-I)和6个月后(CMR-II)分别进行了CMR检测。所有患者在CMR-I期均表现出了心肌水肿,并有31名患者在CMR-II持续存在心肌水肿。CMR-I期

JACC:伊伏洛单抗可明显降低急性冠脉综合征患者早期胆固醇水平

尽管指南推荐急性冠脉综合征(ACS)患者应在住院期间启动高强度他汀类药物治疗,但低密度脂蛋白胆固醇(LDL-C)的目标水平经常达不到。本研究的目的旨在伊伏洛单抗(evolocumab)在ACS患者急性住院期间的降脂效果和可行性。本次随机双盲对照试验纳入分析了308例LDL-C水平增高的ACS住院患者,患者随机分成皮下注射伊伏洛单抗组或安慰剂组。主要终点事件是基线到8周LDL-C水平的变化百分比。大

Nat Med:滴血验病!这项血液检测揭晓肾脏和心血管疾病危险系数

格拉斯哥大学的研究者在《Nature Medicine》杂志上,提出了一项精确而简单的血液测试,可以衡量肾脏和心血管疾病风险。